The University has begun an investigation into the matter, pursuant to the University’s non-discrimination policy. Discrimination and harassment are antithetical to the University of Chicago’s values ...

Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today announced that initial Phase 1 clinical results with PLX-4545, a selective IKZF2 molecular glue degrader, ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...